Mercator Medical S.A., together with its subsidiaries, produces medical gloves and distributes medical disposables in Europe, Russia, and internationally. More Details
Flawless balance sheet and undervalued.
Share Price & News
How has Mercator Medical's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MRC is more volatile than 75% of Polish stocks over the past 3 months, typically moving +/- 10% a week.
Volatility Over Time: MRC's weekly volatility has decreased from 17% to 10% over the past year, but is still higher than 75% of Polish stocks.
7 Day Return
PL Medical Equipment
1 Year Return
PL Medical Equipment
Return vs Industry: MRC exceeded the Polish Medical Equipment industry which returned 89.4% over the past year.
Return vs Market: MRC exceeded the Polish Market which returned 31.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Mercator Medical's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StMercator Medical's (WSE:MRC) Promising Earnings May Rest On Soft Foundations
1 month ago | Simply Wall StWhat Kind Of Investors Own Most Of Mercator Medical S.A. (WSE:MRC)?
7 months ago | Simply Wall StHow Does Mercator Medical's (WSE:MRC) CEO Pay Compare With Company Performance?
Is Mercator Medical undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MRC (PLN240.8) is trading below our estimate of fair value (PLN17476.42)
Significantly Below Fair Value: MRC is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MRC is good value based on its PE Ratio (2.1x) compared to the European Medical Equipment industry average (37.4x).
PE vs Market: MRC is good value based on its PE Ratio (2.1x) compared to the Polish market (14.8x).
Price to Earnings Growth Ratio
PEG Ratio: MRC's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: MRC is good value based on its PB Ratio (1.9x) compared to the PL Medical Equipment industry average (4.6x).
How is Mercator Medical forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MRC's earnings are forecast to decline over the next 3 years (-46.6% per year).
Earnings vs Market: MRC's earnings are forecast to decline over the next 3 years (-46.6% per year).
High Growth Earnings: MRC's earnings are forecast to decline over the next 3 years.
Revenue vs Market: MRC's revenue is expected to decline over the next 3 years (-20.8% per year).
High Growth Revenue: MRC's revenue is forecast to decline over the next 3 years (-20.8% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MRC's Return on Equity is forecast to be high in 3 years time
How has Mercator Medical performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MRC has a high level of non-cash earnings.
Growing Profit Margin: MRC's current net profit margins (54.8%) are higher than last year (3.6%).
Past Earnings Growth Analysis
Earnings Trend: MRC's earnings have grown significantly by 92.6% per year over the past 5 years.
Accelerating Growth: MRC's earnings growth over the past year (5184%) exceeds its 5-year average (92.6% per year).
Earnings vs Industry: MRC earnings growth over the past year (5184%) exceeded the Medical Equipment industry 23.7%.
Return on Equity
High ROE: MRC's Return on Equity (91.4%) is considered outstanding.
How is Mercator Medical's financial position?
Financial Position Analysis
Short Term Liabilities: MRC's short term assets (PLN1.4B) exceed its short term liabilities (PLN329.7M).
Long Term Liabilities: MRC's short term assets (PLN1.4B) exceed its long term liabilities (PLN6.5M).
Debt to Equity History and Analysis
Debt Level: MRC's debt to equity ratio (0.05%) is considered satisfactory.
Reducing Debt: MRC's debt to equity ratio has reduced from 67.8% to 0.05% over the past 5 years.
Debt Coverage: MRC's debt is well covered by operating cash flow (137399.5%).
Interest Coverage: MRC's interest payments on its debt are well covered by EBIT (930.4x coverage).
What is Mercator Medical current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: MRC's dividend (0.21%) isn’t notable compared to the bottom 25% of dividend payers in the Polish market (2%).
High Dividend: MRC's dividend (0.21%) is low compared to the top 25% of dividend payers in the Polish market (5.88%).
Stability and Growth of Payments
Stable Dividend: MRC is not paying a notable dividend for the Polish market, therefore no need to check if payments are stable.
Growing Dividend: MRC is not paying a notable dividend for the Polish market, therefore no need to check if payments are increasing.
Current Payout to Shareholders
Dividend Coverage: MRC is not paying a notable dividend for the Polish market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MRC's dividend in 3 years as they are not forecast to pay a notable one for the Polish market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Wieslaw Zyznowski (56 yo)
Dr. Wieslaw Zyznowski has been the Chairman of Management Board at Mercator Medical Spólka Akcyjna since 2010. In the 90s Dr. Zyznowski co-founded the Mercator. From 1991 to 2001 he served as (apart from a...
CEO Compensation Analysis
Compensation vs Market: Wieslaw's total compensation ($USD123.63K) is below average for companies of similar size in the Polish market ($USD526.36K).
Compensation vs Earnings: Wieslaw's compensation has been consistent with company performance over the past year.
Experienced Management: MRC's management team is considered experienced (2.4 years average tenure).
Experienced Board: MRC's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Mercator Medical S.A.'s company bio, employee growth, exchange listings and data sources
- Name: Mercator Medical S.A.
- Ticker: MRC
- Exchange: WSE
- Founded: 1989
- Industry: Health Care Supplies
- Sector: Healthcare
- Market Cap: zł2.422b
- Shares outstanding: 10.35m
- Website: https://mercatormedical.eu
Number of Employees
- Mercator Medical S.A.
- Heleny Modrzejewskiej 30
Mercator Medical S.A., together with its subsidiaries, produces medical gloves and distributes medical disposables in Europe, Russia, and internationally. The company offers surgical gloves for conducting ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/06/24 17:36|
|End of Day Share Price||2021/06/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.